Abstract

Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib as Monotherapy and in Combination with Cetuximab in Patients with KRAS G12C-Mutated Colorectal Cancer

Sunday, September 19, 2021 - 2:47pm

Results showed that adagrasib alone and with cetuximab demonstrated significant clinical activity and broad disease control in these patients.

Key Points: 
  • Results showed that adagrasib alone and with cetuximab demonstrated significant clinical activity and broad disease control in these patients.
  • "The positive results presented today show that adagrasib alone or in combination with cetuximab may improve clinical outcomes in patients with colorectal cancer harboring a KRASG12C mutation."
  • Adagrasib monotherapy and in combination with cetuximab was well-tolerated in this study, with a manageable safety profile.
  • Treatment related adverse events led to treatment discontinuation in 6% of patients who received combination therapy and in none (0%) of those who received adagrasib monotherapy.

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer

Saturday, September 18, 2021 - 2:05pm

These results highlight the critical role KEYTRUDA can play in improving outcomes for certain women with persistent, recurrent or metastatic cervical cancer.

Key Points: 
  • These results highlight the critical role KEYTRUDA can play in improving outcomes for certain women with persistent, recurrent or metastatic cervical cancer.
  • Cervical cancer is the fourth most commonly diagnosed cancer in women and the fourth leading cause of cancer-related death in women globally.
  • Selected KEYTRUDA (pembrolizumab) Indications in the U.S.
    KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.
  • KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.

Ipsen: ESMO 2021: Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer

Saturday, September 18, 2021 - 5:30am

Grade 3/4 TEAEs occurred in 62% of patients who received Cabometyx vs. 28% for placebo, with no treatment-related grade 5 events.

Key Points: 
  • Grade 3/4 TEAEs occurred in 62% of patients who received Cabometyx vs. 28% for placebo, with no treatment-related grade 5 events.
  • For people living with advanced metastatic castration-resistant prostate cancer, the prognosis is often poor and the potential of new innovative therapies is critically important.
  • Additional endpoints include safety, overall survival and quality of life.2 More information about this trial is available at ClinicalTrials.gov .
  • A total of 651 patients (23% favorable risk, 58% intermediate risk, 20% poor risk; 25% PD-L1 1%) were randomized to Cabometyx plus Opdivo (n = 323) versus sunitinib (n = 328).

Secondcell Bio Publishes Biotechnology for Improved Drug Discovery Originating from The Rockefeller University

Wednesday, September 15, 2021 - 3:00pm

"Little more than a random and highly inefficient enterprise, drug discovery today is "garbage in, garbage out" enterprise.

Key Points: 
  • "Little more than a random and highly inefficient enterprise, drug discovery today is "garbage in, garbage out" enterprise.
  • Currently, the industry average failure rate for drug discovery programs in pharmaceutical companies is reported to be approximately 98%.
  • This work was performed by Chromocell Corporation, a biotechnology company spun out of The Rockefeller University based upon the technology.
  • Secondcell, Secondcell Bio, Cellbrary, Cellbraries, Chromo-Plasmid, pChromo-Plasmid, Chromo-Tag, Drugomics, Drug Discovery at Scale, and the Secondcell Bio logo are trademarks of Secondcell Bio, LLC.

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021

Tuesday, September 14, 2021 - 4:36am

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

Key Points: 
  • In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.
  • Eisai positions oncology as a key therapeutic area and is aiming to discover revolutionary new medicines with the potential to cure cancer.
  • This release discusses investigational compounds and investigational uses for FDA-approved products.
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

Incyte Announces Ruxolitinib Cream Data Accepted for Presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

Monday, September 13, 2021 - 9:30pm

These data from the Phase 3 TRuE-V program underscore our commitment to bringing new therapies to patients with challenging skin diseases.

Key Points: 
  • These data from the Phase 3 TRuE-V program underscore our commitment to bringing new therapies to patients with challenging skin diseases.
  • Efficacy and Safety of Ruxolitinib Cream for the Treatment of Vitiligo: 24-Week Results From 2 Randomized, Double-Blind Phase 3 Studies (Abstract #D3T01.2A.
  • Session: Atopic dermatitis/Eczema)
    Efficacy of Ruxolitinib Cream among Patients with Atopic Dermatitis Based on Previous Medication History (encore) (Abstract #P0192.
  • Ruxolitinib cream is a proprietary formulation of Incytes selective JAK1/JAK2 inhibitor ruxolitinib that has been designed for topical application.

Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published

Monday, September 13, 2021 - 8:23am

Dr Debashis Sarker, Kings College, London, as an e-poster (number 527P) at ESMO on Thursday September 16.

Key Points: 
  • Dr Debashis Sarker, Kings College, London, as an e-poster (number 527P) at ESMO on Thursday September 16.
  • Medivir will host a conference call to update on the progress and plans for the MIV-818 program at 15.00 CET on September 16.
  • It has the potential to become the first liver-targeted and orally administered drug for patients with HCC and other forms of liver cancer.
  • MIV-818 has completed a phase 1b monotherapy study, and a combination study in HCC is now planned to be initiated during the second half of 2021.

CGTN: GAUC to hold global youth summit on a zero carbon future

Tuesday, August 24, 2021 - 7:52pm

To mobilize, showcase, and maximize young people's strength in tackling climate change, the Global Alliance of Universities on Climate (GAUC) announces the ClimateX Summit - a global initiative led by GAUC to engage youth around the world.

Key Points: 
  • To mobilize, showcase, and maximize young people's strength in tackling climate change, the Global Alliance of Universities on Climate (GAUC) announces the ClimateX Summit - a global initiative led by GAUC to engage youth around the world.
  • ClimateX aims to help move the world towards a Net-Zero Carbon Future.
  • -Voice:In partnership with the COP26 Universities Network, this track calls for short video clips from global youth, communicating their thoughts on climate change.
  • GAUC will pursue this mission by promoting exchange and cooperation among member universities and providing leadership in global higher education efforts to address climate change.

CGTN: GAUC to hold global youth summit on a zero carbon future

Tuesday, August 24, 2021 - 7:31pm

To mobilize, showcase, and maximize young people's strength in tackling climate change, the Global Alliance of Universities on Climate (GAUC) announces the ClimateX Summit - a global initiative led by GAUC to engage youth around the world.

Key Points: 
  • To mobilize, showcase, and maximize young people's strength in tackling climate change, the Global Alliance of Universities on Climate (GAUC) announces the ClimateX Summit - a global initiative led by GAUC to engage youth around the world.
  • ClimateX aims to help move the world towards a Net-Zero Carbon Future.
  • -Voice:In partnership with the COP26 Universities Network, this track calls for short video clips from global youth, communicating their thoughts on climate change.
  • GAUC will pursue this mission by promoting exchange and cooperation among member universities and providing leadership in global higher education efforts to address climate change.

Data from Medivir's MIV-818 phase 1b study to be presented at the ESMO Congress

Thursday, August 5, 2021 - 8:05am

The Abstract will be released on the ESMO website 13 September 00.05 CEST ( https://www.esmo.org/meetings/esmo-congress-2021 ).

Key Points: 
  • The Abstract will be released on the ESMO website 13 September 00.05 CEST ( https://www.esmo.org/meetings/esmo-congress-2021 ).
  • The results from the completed phase 1b monotherapy dose escalation part of the study (e-poster presentation number 527P) is scheduled for presentation during the ESMO congress 16-21 September.
  • It has the potential to become the first liver-targeted and orally administered drug for patients with HCC and other forms of liver cancer.
  • MIV-818 has completed a phase 1b monotherapy study, and a combination study in HCC is now planned to be initiated during the second half of 2021.